Omeros Reports Preliminary Results From Critically Ill COVID-19 Patients Treated With Narsoplimab

Omeros Corp. (OMER) announced preliminary results from the second cohort of critically ill COVID-19 patients treated with narsoplimab in Bergamo, Italy. 80% of the patients were recovered, survived and discharged.

Meanwhile 2 deaths were occurred. This is because of 76-year-old man had complications of pre-existing cardiomyopathy. He received 3 doses of narsoplimab;
68-year-old man had multi-organ failure. narsoplimab dosing was initiated after 13 days of intubation.

The patients in the study were part of the "second surge" of COVID-19 in Italy.

Narsoplimab is the company's lead inhibitor of mannan-binding lectin-associated serine protease 2 (MASP-2), the effector enzyme of the lectin pathway of complement.

The COVID-19 patients in this group were even sicker than those in the first cohort of patients treated with narsoplimab at institution during the pandemic's outbreak, the company said in a statement.

Narsoplimab is being evaluated in the I-SPY COVID-19 Trial, an adaptive platform clinical trial enrolling critically ill COVID-19 patients. The trial is sponsored by Quantum Leap Healthcare Collaborative and is funded in part by the United States government through the Biomedical Advanced Research and Development Authority (BARDA).

For comments and feedback contact: editorial@rttnews.com

Business News

Follow RTT